.jpg)
Mar 7, 2023
Aravax initiates Phase 2 peanut allergy clinical trials in Australia
8 March 2023, Melbourne, Australia: Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are...
Dec 19, 2022
Aravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmile
20 December 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company developing the first safe, convenient, and...
May 5, 2022
Aravax appoints Dr Brett Haumann to Board of Directors
06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy...
Mar 3, 2022
Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins...
Aug 26, 2021
Aravax appoints Principal Investigators for PVX108 Phase 2 trials in United States and Australia
27 August 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
Jul 12, 2021
Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021.
13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...